Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2020)
17 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 24, 2020
Slide 1: Chairman's 2020 AGM Address
ASX ANNOUNCEMENT 24 November 2020 Chairman’s 2020 AGM Address For personal use only Good morning and welcome to this year’s Annual General Meeting of Cynata Therapeutics Ltd. I am Geoff Brooke, the Non-Executive Chairman. Present with me today is Dr Ross Macdonald, the Managing Director and Chief Ex
Slide 2: Chairman's 2020 AGM Address (continued)
scheme of arrangement. While the parties ultimately withdrew from discussions, we are encouraged by the further commercial interest we are receiving and continue to actively engage strategic parties to explore potential collaboration and partnering opportunities in order to deliver shareholder value
Slide 3: A Next Generation Stem Cell Therapeutics Company - AGM Presentation
For personal use only A Next Generation Stem Cell Therapeutics Company AGM Presentation Dr. Ross Macdonald (CEO and MD) Dr. Kilian Kelly (COO) 24 November 2020
Slide 4: Important information
Important information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necess
Slide 5: Agenda
For personal use only Agenda 1 2020 Highlights: driving clinical and commercial success 2 Validated strategy: multiple options to maximise shareholder value 3 Significant markets: attractive regenerative medicine industry with value upside 4 Outstanding GvHD results: places Cynata in a strong positi
Slide 6: Year in review: 2020 Highlights
Year in review: 2020 Highlights For personal use only Rapid ethics approval Commencement of Received UK and Australian and commencement for osteoarthritis Phase 3 clinical regulatory approval to Phase 2 COVID-19 trial trial, funded by a NHMRC grant commence a Phase 2 trial in CLI GvHD Phase
Slide 7: Multiple options to create shareholder value
Multiple options to create shareholder value Cynata is executing on a validated scientific and commercial vision and continually assesses pathways to optimise shareholder value For personal use only Build value in platform License / partner Strategic exit / independently with big Pharma merger Clini
Slide 8: Cynata well placed in the regenerative medicine market
Cynata well placed in the regenerative medicine market While it is the nature of the biotech industry that development is uncertain and takes a long time, Cynata is at the forefront of stem cell technology and ideally placed as global interest continues to grow in MSCs For personal use only Global i
Slide 9: Valuation comparisons
Valuation comparisons Significant potential for Cynata when compared to other stem cell-therapy companies For personal use only US$4.34bn3 Significant potential for Cynata US$1.52bn1 US$1.00bn2 Market Capitalisation: US$0.07bn1 Company Clinical stage GvHD: Phase 1 complete Parkinson’s disease Multip
Slide 10: Clinical development overview & outlook
For personal use only Clinical development overview & outlook Dr. Kilian Kelly Chief Operating Officer 8
Slide 11: Phase 1 clinical trial results
Phase 1 clinical trial results Outstanding results in the world-first allogeneic iPSC-derived therapy trial in steroid-resistant acute graft- versus-host disease (GvHD) places Cynata in a strong position to accelerate clinical development For personal use only Key clinical trial results1 - demonstra
Slide 12: Phase 1 results published in Nature Medicine
Phase 1 results published in Nature Medicine Cynata featured on cover of prestigious journal For personal use only Nature • A biomedical research journal that publishes cutting-edge Medicine results journal • Articles are selected for their potential interest, impact and implications for the biomedi
Slide 13: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Cells donated Conventional process MSCs For personal use only The current Cells from MSC isolation MSC expansion Cellular therapies multiple donors administered conventional manufacturing process is sub optimal Substantial variability Limit
Slide 14: FDA focus on manufacturing
FDA focus on manufacturing Cynata‘s Cymerus process actively addresses some of the key areas that the FDA is likely to focus on For personal use only Potential issues raised Key advantages underpinning Cymerus™ “The issue of reliable prediction of Product derived from a single donor provides a hig
Slide 15: Cymerus platform
Cymerus platform Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Crohn’s Disease Others Osteoarthritis Fistula (funded by NHMRC) Coronary Artery Disease Potential future target areas Phase 3 Diabetic Recruiting1 wounds Brain cancer / Graft v
Slide 16: Development pipeline
Development pipeline Broad, advanced development pipeline For personal use only Pre-clinical Phase 1 Phase 2 Phase 3 Status and key catalysts Fujifilm responsible for all updates and ongoing development via global license agreement; GvHD US$2m milestone payment on Phase 2 completion Accelerated to P
Slide 17: Contact details
For personal use only Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street ross.macdonald@cynata.com Carlton Victoria 3053 www.cynata.com Australia
Cynata Therapeutics — Shareholder Meeting (November 2020) on 6ix